NO2968302T3 - - Google Patents

Info

Publication number
NO2968302T3
NO2968302T3 NO14725812A NO14725812A NO2968302T3 NO 2968302 T3 NO2968302 T3 NO 2968302T3 NO 14725812 A NO14725812 A NO 14725812A NO 14725812 A NO14725812 A NO 14725812A NO 2968302 T3 NO2968302 T3 NO 2968302T3
Authority
NO
Norway
Application number
NO14725812A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2968302T3 publication Critical patent/NO2968302T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO14725812A 2012-10-26 2014-03-14 NO2968302T3 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261718966P 2012-10-26 2012-10-26

Publications (1)

Publication Number Publication Date
NO2968302T3 true NO2968302T3 (cg-RX-API-DMAC7.html) 2018-02-03

Family

ID=50545344

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14725812A NO2968302T3 (cg-RX-API-DMAC7.html) 2012-10-26 2014-03-14

Country Status (22)

Country Link
US (2) US9777038B2 (cg-RX-API-DMAC7.html)
EP (1) EP2912013B1 (cg-RX-API-DMAC7.html)
JP (1) JP6272888B2 (cg-RX-API-DMAC7.html)
KR (1) KR102068381B1 (cg-RX-API-DMAC7.html)
CN (2) CN108250264A (cg-RX-API-DMAC7.html)
AU (1) AU2013334122B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015009395A2 (cg-RX-API-DMAC7.html)
CA (1) CA2889592A1 (cg-RX-API-DMAC7.html)
CY (1) CY1119731T1 (cg-RX-API-DMAC7.html)
DK (1) DK2912013T3 (cg-RX-API-DMAC7.html)
ES (1) ES2655034T3 (cg-RX-API-DMAC7.html)
HK (1) HK1253301A1 (cg-RX-API-DMAC7.html)
HU (1) HUE036887T2 (cg-RX-API-DMAC7.html)
IL (1) IL238454B (cg-RX-API-DMAC7.html)
MX (1) MX361653B (cg-RX-API-DMAC7.html)
NO (1) NO2968302T3 (cg-RX-API-DMAC7.html)
NZ (2) NZ745013A (cg-RX-API-DMAC7.html)
PL (1) PL2912013T3 (cg-RX-API-DMAC7.html)
PT (1) PT2912013T (cg-RX-API-DMAC7.html)
SG (1) SG11201503247UA (cg-RX-API-DMAC7.html)
SM (1) SMT201700602T1 (cg-RX-API-DMAC7.html)
WO (1) WO2014066819A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013334122B2 (en) 2012-10-26 2017-11-02 Intercept Pharmaceuticals, Inc. Process for preparing bile acid derivatives
US10407462B2 (en) 2014-05-29 2019-09-10 Bar Pharmaceuticals S.R.L. Cholane derivatives for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases
US10131688B2 (en) 2014-11-19 2018-11-20 NZP UK Limited 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal FXR modulators
US10538550B2 (en) 2014-11-19 2020-01-21 NZP UK Limited 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal FXR modulators
KR102526631B1 (ko) 2014-11-19 2023-04-27 엔제트피 유케이 리미티드 스테로이드 fxr 조절인자를 제조하기 위한 중간체로서의 6-알킬-7-하이드록시-4-엔-3-온 스테로이드
TWI688571B (zh) 2014-11-19 2020-03-21 英商Nzp英國有限公司 化合物(四)
CN104672290B (zh) * 2015-01-05 2017-06-06 北京普禄德医药科技有限公司 一种用于预防或治疗fxr‑介导的疾病的药物及其制备方法和用途
EA036404B1 (ru) 2015-02-06 2020-11-06 Интерсепт Фармасьютикалз, Инк. Фармацевтические композиции для комбинированной терапии
EP3353189A4 (en) * 2015-09-24 2019-06-19 Intercept Pharmaceuticals, Inc. METHOD AND INTERMEDIATE PRODUCTS FOR THE PREPARATION OF GALLENIC ACID DERIVATIVES
MX2018005520A (es) * 2015-11-06 2018-08-01 Intercept Pharmaceuticals Inc Metodos para preparacion de acido obeticolico y derivados de los mismos.
WO2017142895A1 (en) * 2016-02-15 2017-08-24 Regents Of The University Of Minnesota Compositions and methods for treating clostridium associated diseases
WO2017180577A1 (en) 2016-04-13 2017-10-19 Intercept Pharmaceuticals, Inc. Methods of treating cancer
TW201738254A (zh) 2016-04-19 2017-11-01 英特賽普醫藥品公司 奧貝膽酸及其衍生物之製備方法
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
CA3038534A1 (en) * 2016-09-30 2018-04-05 Intercept Pharmaceuticals, Inc. Crystalline forms of a bile acid derivative
WO2019023103A1 (en) 2017-07-24 2019-01-31 Intercept Pharmaceuticals, Inc. BILIARY ACID DERIVATIVES WITH ISOTOPIC MARKING
US11059854B2 (en) * 2017-07-26 2021-07-13 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Method for preparing steroid derivative FXR agonist
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
SG11202113155XA (en) 2019-05-30 2021-12-30 Intercept Pharmaceuticals Inc Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
US20230331766A1 (en) 2020-09-18 2023-10-19 Seoul National University R&Db Foundation Method for mass-producing sodium taurodeoxycholate

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216015A (en) * 1991-02-05 1993-06-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having hypocholesterolemic properties
AU2002308295B2 (en) 2001-03-12 2007-08-23 Intercept Pharmaceuticals, Inc. Steroids as agonists for FXR
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
PT2040713E (pt) * 2006-06-27 2014-10-13 Intercept Pharmaceuticals Inc Para a prevenção ou o tratamento de doenças ou estados clínicos mediados por fxr
US9943614B2 (en) * 2008-06-17 2018-04-17 Brigham Young University Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods
EA020310B1 (ru) * 2008-07-30 2014-10-30 Интерсепт Фармасьютикалз, Инк. Модуляторы рецептора tgr5 и их применение
CN102282157B (zh) * 2008-11-19 2017-02-22 英特塞普特医药品公司 G蛋白偶联受体5(tgr5)调节剂及其使用方法
AU2013334122B2 (en) 2012-10-26 2017-11-02 Intercept Pharmaceuticals, Inc. Process for preparing bile acid derivatives

Also Published As

Publication number Publication date
NZ707389A (en) 2018-08-31
US10202414B2 (en) 2019-02-12
CN108250264A (zh) 2018-07-06
IL238454B (en) 2018-11-29
EP2912013A4 (en) 2016-06-01
KR20150074062A (ko) 2015-07-01
SG11201503247UA (en) 2015-06-29
IL238454A0 (en) 2015-06-30
HK1214239A1 (zh) 2016-07-22
HUE036887T2 (hu) 2018-08-28
WO2014066819A1 (en) 2014-05-01
EP2912013B1 (en) 2017-10-11
KR102068381B1 (ko) 2020-01-20
AU2013334122B2 (en) 2017-11-02
US9777038B2 (en) 2017-10-03
SMT201700602T1 (it) 2018-03-08
CY1119731T1 (el) 2018-06-27
PT2912013T (pt) 2018-01-03
DK2912013T3 (en) 2018-01-15
BR112015009395A2 (pt) 2017-07-04
CN105102425B (zh) 2018-04-10
ES2655034T3 (es) 2018-02-16
JP2015533852A (ja) 2015-11-26
JP6272888B2 (ja) 2018-01-31
AU2013334122A1 (en) 2015-05-14
CN105102425A (zh) 2015-11-25
MX361653B (es) 2018-12-13
US20180079776A1 (en) 2018-03-22
MX2015005286A (es) 2015-10-29
EP2912013A1 (en) 2015-09-02
PL2912013T3 (pl) 2018-05-30
US20150291653A1 (en) 2015-10-15
HK1253301A1 (zh) 2019-06-14
NZ745013A (en) 2019-08-30
CA2889592A1 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
BR112014017614A2 (cg-RX-API-DMAC7.html)
BR112014017625A2 (cg-RX-API-DMAC7.html)
BR112014017592A2 (cg-RX-API-DMAC7.html)
BR112014017607A2 (cg-RX-API-DMAC7.html)
AR092201A1 (cg-RX-API-DMAC7.html)
BR112014025793A2 (cg-RX-API-DMAC7.html)
BR112014024753A2 (cg-RX-API-DMAC7.html)
BR112013027865A2 (cg-RX-API-DMAC7.html)
BR112014017609A2 (cg-RX-API-DMAC7.html)
BR112014017634A2 (cg-RX-API-DMAC7.html)
BR112014017588A2 (cg-RX-API-DMAC7.html)
BR112014017647A2 (cg-RX-API-DMAC7.html)
BR112014013184A8 (cg-RX-API-DMAC7.html)
BR112014017618A2 (cg-RX-API-DMAC7.html)
BR112014017627A2 (cg-RX-API-DMAC7.html)
BR112014017623A2 (cg-RX-API-DMAC7.html)
BR112014017621A2 (cg-RX-API-DMAC7.html)
BR112014017631A2 (cg-RX-API-DMAC7.html)
BR112014017622A2 (cg-RX-API-DMAC7.html)
BR112014017589A2 (cg-RX-API-DMAC7.html)
BR112014019729A2 (cg-RX-API-DMAC7.html)
BR112014017600A2 (cg-RX-API-DMAC7.html)
BR112014017591A2 (cg-RX-API-DMAC7.html)
BR112014017593A2 (cg-RX-API-DMAC7.html)
BR112014017596A2 (cg-RX-API-DMAC7.html)